Nicolette Centanni

Nicolette Centanni

Auto-generated profile, based on publicly available information

Nicolette Centanni

Maine Medical Center Portland Maine USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2024 in JACCP: Journal of the American College of Clinical Pharmacy
Verified
Journal Article
Closed access
JMJay L. Martello
Jay L. Martello
ZDZack Jules Dumont
Zack Jules Dumont
WBWiyanna Bruck
Wiyanna Bruck
MBMitchell S. Buckley
Mitchell S. Buckley
CBChristopher Buckley
Christopher Buckley
SWSharon Wu
Sharon Wu

1 July 2021 in Mental Health Clinician
Verified
Journal Article
Open access
PDF file
NCNicolette R. Centanni
Nicolette R. Centanni
WCWendy Y. Craig
Wendy Y. Craig
DWDena L. Whitesell
Dena L. Whitesell
WZWesley R. Zemrak
Wesley R. Zemrak
SNStephanie D. Nichols
Stephanie D. Nichols
Introduction: This study assessed the use, tolerability, and safety of anticoagulation via direct oral anticoagulants or warfarin in medical and psychiatric inpatients receiving ECT. Methods: This retrospective cohort study included 32 patients who received ECT while on either a direct oral anticoagulant (9) or warfarin (23) and spanned 247 encounters at Maine Medical Center between December 2012 and December 2018. Data are presented descriptively and analyzed using SPSS version 25 and Microsoft Excel version 2016. Results: Among the 247 ECT patient encounters, there were few major adverse effects of ECT in this medically complex population. These adverse effects included headache during 4 encounters (1.6%), respiratory distress during 2 encounters (0.8%) and a cardiovascular event during 1 encounter (0.4%). One patient (3.1%) who was receiving concurrent rivaroxaban and venlafaxine experienced gastrointestinal bleeding that was determined to be unrelated to ECT. One patient on fluoxetine and warfarin experienced hemoptysis thought to be secondary to epistaxis. No other major bleeding or clotting event occurred during an ECT session nor for the duration of the hospitalization. Discussion: Direct oral anticoagulants and warfarin appear safe in the treatment of patients with atrial fibrillation or acute venous thromboembolism who are receiving concomitant ECT. Prospective studies are needed to confirm these findings.

21 January 2025 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
NCNicolette Centanni
Nicolette Centanni
KGKayla Garvey
Kayla Garvey
EMElizabeth Mullany
Elizabeth Mullany
SNStephanie Nichols
Stephanie Nichols

1 June 2025 in Mental Health Clinician
Verified
Journal Article
Open access
KGKayla Garvey
Kayla Garvey
KGKobi Griffith
Kobi Griffith
ECEmily Carter
Emily Carter
WCWendy Craig
Wendy Craig
DGDavid J. Gagnon
David J. Gagnon
NCNicolette Centanni
Nicolette Centanni
Introduction: Delirium affects nearly half of hospitalized older adults and is associated with prolonged hospitalization, dementia, and death. The behavioral manifestations of delirium are generally managed with antipsychotics, but there is growing interest in alternative medical therapy, including guanfacine. Methods: This retrospective cohort study included patients ≥65 years of age admitted to Maine Medical Center between January 2021 and April 2023 and treated with guanfacine for delirium management on a non-ICU unit. Effectiveness outcomes included antipsychotic use and dose as well as a change in positive delirium screen after guanfacine initiation. Safety outcomes included incidence of hypotension, bradycardia, or transfer to ICU. Results: A total of 56 patients who received at least 1 dose of guanfacine were evaluated, and 38 patients (68%) with complete data for days −1 to +2 were included in the effectiveness analysis. Before guanfacine initiation, 22/38 patients (58%) were receiving an antipsychotic medication, compared with 18/38 (47%) after guanfacine initiation (p = 0.86). Patients received a median (interquartile range) 6.4 (3.3 to 16) olanzapine equivalents (OE) before guanfacine was initiated and 4.2 (1.7 to 10.0) OE after guanfacine (absolute difference 2.2 OE; relative difference, 34 %; p = 0.8). All 56 patients were included in the safety analysis; 21 (38%) experienced hypotension, and of these, 7 (33%) patients required intervention. Twenty-three (41%) experienced bradycardia while on guanfacine, resulting in 1 patient being transferred to the ICU. Discussion: Upon initiation of guanfacine, patients with delirium had a reduction in daily antipsychotic exposure and a decrease in positive delirium screens. However, guanfacine was associated with hypotension and bradycardia.

15 April 2024 in Hospital Pharmacy
Verified
Journal Article
Closed access
NCNicolette Centanni
Nicolette Centanni
TMTaylor Mezoian
Taylor Mezoian
JGJohn Gilboy
John Gilboy
JEJessica Evans
Jessica Evans
NHNicole Hudak
Nicole Hudak
LGLesley Gordon
Lesley Gordon
Introduction: Alcohol is the most common substance use disorder in the United States. Despite this prevalence, there remains significant heterogeneity in medical management of alcohol withdrawal syndrome (AWS). While the 2020 American Society of Addition Medicine continues to recommend the use of benzodiazepines as first-line therapy for AWS, there is increasing use of phenobarbital in patients at high risk of severe AWS. Despite phenobarbital’s favorable pharmacologic profile, historically, clinical utilization on general medicine services has been low and often restricted. In this project, we have examined practice patterns and associated clinical outcomes in adult patients experiencing AWS on the general medicine service pre and post implementation of a phenobarbital-based protocol for the treatment of severe AWS at our institution. Methods: This quality improvement study evaluated changes in management of AWS on general medicine units associated with implementation of a phenobarbital-based protocol and order set in the electronic medical record (EMR). Our primary outcome measures were receipt of a phenobarbital loading dose, concomitant benzodiazepine administration, and total benzodiazepine dose. Safety outcomes were also explored to assess clinical impacts of this protocol implementation. The project was determined “not research” by our Institutional Review Board. Results: Phenobarbital-protocol implementation was associated with increased frequency of receiving a phenobarbital loading dose (49.5% vs 9.4%; P < .001), decreased use of concomitant benzodiazepine/phenobarbital (4.3% vs 28.9%; P < .001), and decreased total benzodiazepine dose (7.8 vs 15.5 mg; P < .001). Regarding safety, there was no significant pre/post difference in the rate of ICU transfer, but among those transferred there was a trend toward decreased mechanical ventilation rate (100% vs 28.6%; P = .051), and a significantly reduced ICU length of stay (median 11 vs 3 days; P = .04). There were no pre/post differences in seizures, delirium or use of adjunct medications. Conclusions: This quality improvement study demonstrates a marked change in provider prescribing practices for treating AWS after implementation of an institutional phenobarbital-based protocol. We observed no difference in overall clinical outcomes after protocol implementation, although a larger follow-up study is needed to confirm this and to further explore the shorter ICU length of stay for patients with AWS postimplementation.